Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Seagen Inc. < Previous 1 2 3 Next > ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma December 10, 2023 From Seagen Inc. Via Business Wire Tickers SGEN TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer December 06, 2023 From Seagen Inc. Via Business Wire Tickers SGEN FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer November 30, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting November 03, 2023 From Seagen Inc. Via Business Wire Tickers SGEN New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate November 02, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress November 01, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer October 22, 2023 From Seagen Inc. Via Business Wire Tickers SGEN TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial October 22, 2023 From Seagen Inc. Via Business Wire Tickers GMAB SGEN Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023 October 16, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023 October 12, 2023 From Seagen Inc. Via Business Wire Tickers SGEN PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial September 22, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone September 04, 2023 From Seagen Inc. Via Business Wire Tickers GMAB SGEN Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer August 16, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum August 02, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023 July 12, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma June 20, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma June 14, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL) June 13, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen Stockholders Approve Acquisition by Pfizer May 30, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen Reports First Quarter 2023 Financial Results April 27, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting April 26, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen to Report First Quarter 2023 Financial Results on April 27, 2023 April 07, 2023 From Seagen Inc. Via Business Wire Tickers SGEN FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer April 03, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting March 14, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Pfizer Invests $43 Billion to Battle Cancer March 13, 2023 From Seagen Inc. Via Business Wire Tickers PFE SGEN Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer March 09, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen to Present at the Cowen 43rd Annual Health Care Conference February 27, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen Reports Fourth Quarter and Full Year 2022 Financial Results February 15, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium February 13, 2023 From Seagen Inc. Via Business Wire Tickers SGEN Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer January 19, 2023 From Seagen Inc. Via Business Wire Tickers SGEN < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.